Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Iovance Biotherapeutics: 3Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/04/2019 | 04:44pm EST

SAN CARLOS, Calif. (AP) _ Iovance Biotherapeutics Inc. (IOVA) on Monday reported a loss of $49.5 million in its third quarter.

On a per-share basis, the San Carlos, California-based company said it had a loss of 40 cents.

The results met Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was also for a loss of 40 cents per share.

Iovance Biotherapeutics shares have more than doubled since the beginning of the year. In the final minutes of trading on Monday, shares hit $20.46, more than doubling in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IOVA at https://www.zacks.com/ap/IOVA

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IOVANCE BIOTHERAPEUTICS, I
12/02Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Decemb..
GL
11/21Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients ..
GL
11/12IOVANCE BIOTHERAPEUTICS : Lytix Biopharma is featured in Finansavisen, talking a..
AQ
11/11IOVANCE BIOTHERAPEUTICS : Announces Updated Phase 2 Clinical Data from the Lifil..
AQ
11/11LYTIX BIOPHARMA ANNOUNCES A CLINICAL : Iova)
AQ
11/08Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifi..
GL
11/07Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Novemb..
GL
11/04IOVANCE BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
AQ
11/04IOVANCE BIOTHERAPEUTICS : 3Q Earnings Snapshot
AQ
11/04IOVANCE BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, F..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -196 M
Net income 2019 -187 M
Finance 2019 318 M
Yield 2019 -
P/E ratio 2019 -16,6x
P/E ratio 2020 -15,1x
EV / Sales2019 infx
EV / Sales2020 108x
Capitalization 3 138 M
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, I
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 35,25  $
Last Close Price 24,87  $
Spread / Highest target 141%
Spread / Average Target 41,7%
Spread / Lowest Target 20,6%
EPS Revisions
Managers
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain D. Dukes Chairman
Timothy E. Morris Secretary, Chief Financial & Accounting Officer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.181.02%3 138
GUARDANT HEALTH, INC.95.74%6 910
GENSCRIPT BIOTECH CORPORATION77.52%4 437
INVITAE CORPORATION54.16%1 646
VERACYTE, INC.138.39%1 465
MIRACA HOLDINGS INC.12.05%1 428